Nani Gelvezon, D.O. Surgery Medicare: Accepting Medicare Assignments Practice Location: 600 N Garfield Ave Ste 210, Monterey Park, CA 91754 Phone: 626-573-8282 Fax: 626-573-8338 |
Danny K Chung, M.D. Surgery Medicare: Medicare Enrolled Practice Location: 2420 Abadejo, La Verne,ca 91750, 201 W Garvey Ave., # 108, Monterey Park, CA 91754 Phone: 626-573-2188 Fax: 626-573-1345 |
Dr. Sean Youngjin Kim, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 600 N Garfield Ave Ste 210, Monterey Park, CA 91754 Phone: 626-573-8282 Fax: 626-573-8338 |
Dr. Yanira Perez, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 850 S Atlantic Boulevard, Ste 305, Monterey Park, CA 91754 Phone: 626-570-6920 Fax: 626-282-3619 |
Shiun T Ker, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 600 N Garfield Ave, Room 306, Monterey Park, CA 91754 Phone: 626-571-8271 Fax: 626-571-8106 |
Dr. Quang T. Vo, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 600 N Garfield Ave Ste 204, Monterey Park, CA 91754 Phone: 714-708-0500 |
Mr. Kenneth T Sim, MD Surgery Medicare: Medicare Enrolled Practice Location: 120 W Hellman Ave Ste 203, Monterey Park, CA 91754 Phone: 626-457-6333 Fax: 626-457-1933 |
News Archive
Unitive Design & Analysis Ltd, a London-based SME, are delighted to announce their success in being awarded a grant by Innovate UK, the UK's innovation agency.
It's called the Silver Tsunami - the increased incidence of cancer with aging, combined with the rapidly aging population means that the Australian health system needs to prepare for an onslaught of cancer diagnoses.
Today's early morning highlights from the major news organizations, including reports about the former Microsoft executive who has been tapped by the Obama administration to take over the repairs of healthcare.gov.
ImmunoCellular Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has given clearance to a physician sponsored investigative new drug (IND) application to initiate a Phase I clinical trial of ICT-121, IMUC's novel dendritic-cell-based vaccine targeting CD-133, an antigen that is highly expressed by multiple solid tumors.
› Verified 2 days ago